Charles Taylor launches its Venture return to work tool

Charles Taylor has developed a tool for managing COVID-19 risk assessments for employees returning to work or resuming international travel.

Designed to help businesses demonstrate that they have taken adequate measures and implemented precautions to protect staff, Venture specifically identifies individual members of staff who are likely to develop severe symptoms of COVID-19, placing them on a scale according to predictive variables. Beyond COVID-19, Venture can also identify globally mobile employees who may be susceptible to wider medical risks.

Venture has been developed in consultation with Charles Taylor’s chief medical officer, Dr Lynn Gordon and Dr Paolo Paredi, honorary consultant and senior researcher at the National Heart and Lung Institute, Imperial College London.

Angela Smith, head of proposition development for Charles Taylor Claims Services, comments, “Venture gives employers the reassurance they need to help staff return to the office or to resume international travel. It ensures that vulnerable individuals are identified accurately and fairly, based on their own individual health profiles – and this sets it apart from other broad-range COVID-19-risk-identification measures.

“Both Venture and our online medical screening tool, Antidote, can be integrated with the range of security and medical assistance services available from Charles Taylor; offering employers a comprehensive and tailored service that helps them meet and exceed their duty of care obligations.”

For the tool to function, employees must first complete a brief online assessment, accessible from any device. The firm says the tool also ensures that employees’ sensitive medical information is withheld from employers.

    Share Story:

Recent Stories